Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR T-Cells for B-Cell Lymphoma
NCT00924326Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2009
- Primary completion
- Sep 2015
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD19 CAR T-cells (Beijing Doing Biomedical) in B cell lymphoma, B-cell leukemia (BCL), sponsored by National Cancer Institute. Started Feb 2009; status: completed.
02
Drugs
Anti-CD19 CAR T-cells (Beijing Doing Biomedical)
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT00924326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924326.